Research Analysts’ Downgrades for March 6th (AKBA, AMD, ARBE, ATGE, AWI, CPB, FET, FUN, MDB, MRVL)

Research Analysts’ downgrades for Thursday, March 6th:

Akebia Therapeutics (NASDAQ:AKBA) was downgraded by analysts at StockNews.com from a hold rating to a sell rating.

Advanced Micro Devices (NASDAQ:AMD) was downgraded by analysts at StockNews.com from a hold rating to a sell rating.

Arbe Robotics (NASDAQ:ARBE) was downgraded by analysts at Maxim Group from a buy rating to a hold rating.

Adtalem Global Education (NYSE:ATGE) was downgraded by analysts at StockNews.com from a strong-buy rating to a buy rating.

Armstrong World Industries (NYSE:AWI) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.

Campbell Soup (NASDAQ:CPB) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating. The firm currently has $37.00 price target on the stock, down from their previous price target of $48.00.

Forum Energy Technologies (NYSE:FET) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.

Cedar Fair (NYSE:FUN) was downgraded by analysts at StockNews.com from a hold rating to a sell rating.

MongoDB (NASDAQ:MDB) was downgraded by analysts at Wells Fargo & Company from an overweight rating to an equal weight rating. The firm currently has $225.00 price target on the stock, down from their previous price target of $365.00.

Marvell Technology (NASDAQ:MRVL) was downgraded by analysts at Summit Insights from a buy rating to a hold rating.

Sinclair (NASDAQ:SBGI) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.

Strategic Education (NASDAQ:STRA) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.

Stryker (NYSE:SYK) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.

Trinity Biotech (NASDAQ:TRIB) was downgraded by analysts at StockNews.com from a hold rating to a sell rating.

VersaBank (NASDAQ:VBNK) was downgraded by analysts at Roth Mkm from a buy rating to a neutral rating. The firm currently has $10.40 price target on the stock, down from their previous price target of $22.00.

JOYY (NASDAQ:YY) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.

Receive News & Ratings for Akebia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.